SIM
CBIO

Spark Investment Management’s Crescent Biopharma CBIO Stock Holding History

Spark Investment Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-245
Closed -$91K – 64
2020
Q2 		$91K Sell
245
-130
-35% -$36.8K 0.33% 51
2020
Q1 		$85K Buy
375
+188
+101% +$71.9K 0.05% 289
2019
Q4 		$98K Buy
+187
New +$101K 0.01% 498
2016
Q3 		– Sell
-114
Closed -$82K – 847
2016
Q2 		$82K Sell
114
-109
-49% -$75.1K 0.01% 719
2016
Q1 		$132K Sell
223
-240
-52% -$123K 0.01% 668
2015
Q4 		$264K Sell
463
-85
-16% -$56.3K 0.03% 514
2015
Q3 		$306K Sell
548
-61
-10% -$44K 0.04% 457
2015
Q2 		$473K Sell
609
-157
-20% -$130K 0.07% 370
2015
Q1 		$636K Buy
766
+135
+21% +$105K 0.09% 320
2014
Q4 		$453K Buy
631
+433
+219% +$339K 0.08% 339
2014
Q3 		$136K Buy
+198
New +$160K 0.02% 559

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Spark Investment Management's CBIO Position: Q3 2020 in Review

Spark Investment Management sold out of Crescent Biopharma (CBIO) in Q3 2020, closing a stake of 245 shares — an estimated $91K sold.

Spark Investment Management first reported a position in CBIO in Q3 2014 and held it in 11 quarters. The position peaked at $636K in Q1 2015. 80 funds tracked by Wall St. Rank hold CBIO as of Q3 2020.

  • Spark Investment Management reported no remaining Crescent Biopharma position as of Q3 2020 after selling out during the quarter.
  • Spark Investment Management sold 245 Crescent Biopharma shares in Q3 2020, an estimated $91K.
  • Spark Investment Management first reported a position in Crescent Biopharma in Q3 2014 and held it in 11 quarters.
  • Spark Investment Management's Crescent Biopharma position peaked at $636K in Q1 2015.
  • 80 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2020.

Based on Spark Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.